Abstract 299P
Background
With the increasing proportion of women surviving carcinoma cervix, quality of life becomes an important issue. Most of the diagnosed women belong to the sexually active group (mean age 50 years). Therefore impact on sexual health is vital. Since there are only few studies on the topic, this study is to assess sexual dysfunction issues in patients treated with multimodality therapy using the LENT SOMA scores.
Methods
The study was prospective. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to postoperative radiotherapy. The mean age was 47.81 years with a range of 2568 years. Completion of LENT SOMA scale and Statistical analysis for sexual dysfunction scores was done- stage wise and treatment wise.
Results
Mean subjective sexual function and satisfaction scores was highest in stage IIIA disease (0.0972) while maximum subjective sexual score was seen in stage IIB disease (0.94). Mean objective score VG (Vagina) was highest in stage IVA and maximum score (0.80) was seen in stage IIIB. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients in which gap between treatment and interview was 11 years and maximum score was highest (0.94) in same group. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients who were treated in earlier years when compared with other patients p value-0.093). Sexual function and satisfaction maximum score was highest in combined surgery and radiotherapy group (0.94) and minimum in RT alone group (0.54). The objective mean score VG (Vagina) was highest in combined surgery and radiotherapy group and maximum score(0.80) was highest in the radiotherapy(+chemo) group.
Conclusions
Currently there is no single self-report measure in routine clinical follow use which is easy to complete and incorporates all aspects of sexual health for people affected by cancer. We used LENT SOMA scale in our study, it provides a comprehensive system to assess treatment induced sexual difficulties to score the impact of radiotherapy morbidity in cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract